Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 139-147

  Chen, Guo ^a   Wang, Ke ^a   Yang, Bing Ya ^a   Tang, Bo ^a   Chen, Jian Xiang ^a   Hua, Zi Chun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenic trioxide; Hepatocellular carcinoma; Oridonin; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ARSENIC TRIOXIDE; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ORIDONIN; PROTEIN BAX; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CHINESE MEDICINE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RABDOSIA; TRADITIONAL MEDICINE; TREATMENT OUTCOME; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DITERPENES, KAURANE; DRUG SYNERGISM; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; NF-KAPPA B; OXIDES; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84455163076     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1210     Document Type: Article

References (37)

1. Hsu C, Cheng JC and Cheng AL: Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. J Formos Med Assoc 103: 483-495, 2004.
2. Leung TW and Johnson PJ: Systemic therapy for hepatocellular carcinoma. Semin Oncol 28: 514-520, 2001.
3. Yeo W, Mok TS, Zee B, et al.: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538, 2005.
4. Douer D and Tallman MS: Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23: 2396-2410, 2005.
5. Sanz MA, Grimwade D, Tallman MS, et al.: Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 113: 1875-1891, 2009.
6. Tallman MS, Andersen JW, Schiffer CA, et al.: All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100: 4298-4302, 2002.
7. Kito M, Akao Y, Ohishi N, Yagi K and Nozawa Y: Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 291: 861-867, 2002.
8. Zhang TC, Cao EH, Li JF, Ma W and Qin JF: Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 35: 1258-1263, 1999.
9. Shen ZY, Zhang Y, Chen JY, et al.: Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts. Oncol Rep 11: 155-159, 2004.
10. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61: 5432-5440, 2001.
11. Nakagawa Y, Akao Y, Morikawa H, et al.: Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70: 2253-2269, 2002.
12. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL and Yang CH: Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 25: 77-84, 2007.
13. Oketani M, Kohara K, Tuvdendorj D, et al.: Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 183: 147-153, 2002.
14. Panthel K, Meinel KM, Sevil Domenech VE, et al.: Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system. Microbes Infect 8: 2539-2546, 2006.
15. Huang J, Wu L, Tashiro S, Onodera S and Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 107: 370-379, 2008.
16. Jin HO, Yoon SI, Seo SK, et al.: Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 72: 1228-1236, 2006.
17. Kang YH, Yi MJ, Kim MJ, et al.: Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res 64: 8960-8967, 2004.
18. Cao L, Du P, Jiang SH, Jin GH, Huang QL and Hua ZC: Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol Cancer Ther 7: 851-861, 2008.
19. Chen G, Wei DP, Jia LJ, et al.: Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. Cancer Sci 100: 2437-2443, 2009.
20. Wang IK, Lin-Shiau SY and Lin JK: Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 35: 1517-1525, 1999.
21. Bratton SB, Lau SS and Monks TJ: The putative benzene metabolite 2,3, 5-tris(glutathion-S-yl)hydroquinone depletes glutathione, stimulates sphingomyelin turnover, and induces apoptosis in HL-60 cells. Chem Res Toxicol 13: 550-556, 2000.
22. Rogalska A, Koceva-Chyla A and Jozwiak Z: Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chem Biol Interact 176: 58-70, 2008.
23. Cartron PF, Bellot G, Oliver L, Grandier-Vazeille X, Manon S and Vallette FM: Bax inserts into the mitochondrial outer membrane by different mechanisms. FEBS Lett 582: 3045-3051, 2008.
24. 2+ and the activation of caspase-3. Anticancer Res 26: 4379-4389, 2006.
25. Gao FH, Hu XH, Li W, et al.: Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 10: 610, 2010.
26. Russmann H, Igwe EI, Sauer J, Hardt WD, Bubert A and Geginat G: Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol 167: 357-365, 2001.
27. Rodgers HKS, Malani A, Willis M and Markowitz A: A phase II study of arsenic trioxide (ATO) in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol (Abst) 28: e14686, 2010.
28. Kim HR, Kim EJ, Yang SH, et al.: Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int J Oncol 28: 1401-1408, 2006.
29. Park JH, Kim EJ, Jang HY, et al.: Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep 20: 379-384, 2008.
30. Park MT, Kang YH, Park IC, et al.: Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells. Mol Cancer Ther 6: 82-92, 2007.
31. Sanchez Y, Amran D, Fernandez C, De Blas E and Aller P: Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK). Int J Cancer 123: 1205-1214, 2008.
32. Yi J, Yang J, He R, et al.: Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 64: 108-116, 2004.
33. Li JX, Shen YQ, Cai BZ, et al.: Arsenic trioxide induces the apop-tosis in vascular smooth muscle cells via increasing intracellular calcium and ROS formation. Mol Biol Rep 37: 1569-1576, 2010.
34. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
35. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849, 2004.
36. Kang SH, Song JH, Kang HK, et al.: Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells. Exp Mol Med 35: 83-90, 2003.
37. Mollinedo F: Survival and apoptotic signals in the action of microtubule-targeting antitumor drugs. Drugs 8: 127-143, 2005.